AA
IRWD icon

AlphaCentric Advisors’s Ironwood Pharmaceuticals IRWD Stock Holding History

AlphaCentric Advisors’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-245,000
Closed -$2.8M – 237
2023
Q4 		$2.8M Sell
245,000
-47,500
-16% -$470K 1.88% 15
2023
Q3 		$2.82M Buy
292,500
+135,000
+86% +$1.32M 1.6% 15
2023
Q2 		$1.68M Buy
+157,500
New +$1.69M 0.93% 38

Other funds holding IRWD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

AlphaCentric Advisors's IRWD Position: Q1 2024 in Review

AlphaCentric Advisors sold out of Ironwood Pharmaceuticals (IRWD) in Q1 2024, closing a stake of 245,000 shares — an estimated $2.8M sold.

AlphaCentric Advisors first reported a position in IRWD in Q2 2023 and held it in 3 quarters. The position peaked at $2.82M in Q3 2023. 261 funds tracked by Wall St. Rank hold IRWD as of Q1 2024.

  • AlphaCentric Advisors reported no remaining Ironwood Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • AlphaCentric Advisors sold 245,000 Ironwood Pharmaceuticals shares in Q1 2024, an estimated $2.8M.
  • AlphaCentric Advisors first reported a position in Ironwood Pharmaceuticals in Q2 2023 and held it in 3 quarters.
  • AlphaCentric Advisors's Ironwood Pharmaceuticals position peaked at $2.82M in Q3 2023.
  • 261 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q1 2024.

Based on AlphaCentric Advisors's 13F filing for Q1 2024, filed 24 Apr 2024.